Abstract
Overview
Introduction
Bone metastases are a complication of some advanced cancers including cancers
of the breast, lung, prostate, kidney and thyroid. The incidence of bone
metastases across these tumor types in the seven major markets is forecasted
to total 225,174 in 2008. While treatment with bisphosphonates reduces the
risk of skeletal complications, they do not improve survival in the majority
of patients.
Scope
- Overview of bone metastases epidemiology, which is currently unknown,
disease mechanisms, complications and diagnosis
- Current treatment options and identification of unmet needs in bone
metastases
- Research and analysis of the bone metastases pipeline with clinical and
commercial assessment of late-phase candidates
- Stakeholder opinions based on qualitative interviews with key opinion
leaders from the US and EU
Highlights
Current bisphosphonate therapy reduces the risk of skeletal complications such
as fractures and bone pain but as yet do not offer a survival advantage in the
majority of patients. More efficacious agents that improve survival and
enhance the quality of life of advanced cancer patients with bone metastases
would be highly welcome.
Survival of bone metastases patients varies according to primary cancer type
and largely remains unchanged with current treatment. In light of this, an
emerging opportunity is the potential of bisphosphonate therapy to prevent
bone metastases when given in early stage cancer patients, for which trials
are ongoing.
Approaching patent expiries for Bondronat and Zometa and the subsequent
availability of cheaper generic versions may raise the barrier to uptake of
more novel but costly emerging agents such as denosumab. However, significant
opportunity exists to succeed in the bone metastases market if newer agents
can demonstrate superior efficacy and/or safety.
Reasons to Purchase
- Gain an insight into the epidemiology trends as the true incidence of bone
metastases is currently unknown
- Identify the limitations of current bone metastases therapy and consider
the remaining unmet needs
- Acquire a detailed appreciation and impartial perspective of the bone
metastases pipeline and identify the key products in late-phase development
| 
View Cart
